Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — Investor Presentation (September 2021)
21 slides from Scopus Biopharma's investor presentation, September 2021
Slide 1: Launch of Duet Therapeutics, a wholly-owned immuno-oncology subsidiary of Scopus BioPharma
Launch of Duet Therapeutics, a wholly-owned immuno-oncology subsidiary of Scopus BioPharma September 2021
Slide 2: Disclaimers
DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding Scopus BioPharma Inc., “Scopus” or the “Company” that are not historical fact, including, but not limited to, statements regarding ex
Slide 3: Scopus BioPharma at a Glance
SCOPUS BIOPHARMA AT A GLANCE Scopus is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need 10-DAY AVG SHARES COMPANY EXCHANGE SYMBOL SHARE PRICE MARKET CAP VOLUME OUTSTANDING Scopus NASDAQ “SCPS” $5.77 $104.4M 1
Slide 4: Duet Therapeutics, a Scopus BioPharma company
DUET THERAPEUTICS, A SCOPUS BIOPHARMA COMPANY On September 2, 2021, Scopus announced the launch of Duet Therapeutics to integrate the management and clinical development of the immuno-oncology assets of Scopus and Olimmune, acquired by Scopus in June 2021 A Scopus BioPharma company
Slide 5: Creating targeted oligonucleotide therapies for treatment-resistant cancers
A Scopus BioPharma company Creating targeted oligonucleotide therapies for treatment- resistant cancers
Slide 6: Duet's platform provides a unique approach to treating hematological malignancies and solid tumor cancers
Duet’s platform provides a unique approach to treating hematological malignancies and solid tumor cancers Investment highlights 6 Bi-functional mode of action Addresses solid tumors Duet’s platform stimulates the immune Duet’s platform targets a fundamental activation and releases immunosuppression,
Slide 7: The Duet technologies create a powerful portfolio of bi-functional molecules
The Duet technologies create a powerful portfolio of bi-functional molecules that hold broad potential across multiple tumor types Technology portfolio 7 Molecule name CpG-STAT3siRNA (DUET-01) CpG-STAT3ASO (DUET-02) CpG-STAT3decoy (DUET-03) CpG ODN STAT3siRNA CpG ODN STAT3ASO CpG ODN STAT3dODN Struc
Slide 8: Duet's pipeline of STAT3 inhibitors
Duet’s pipeline of STAT3 inhibitors includes a suite of technologies and several expansion indications in immuno-oncology Duet pipeline 8 Candidate Program / indication Discovery / optimization IND enabling Phase 1 B-cell non-Hodgkin DUET-01 Target milestone: Dosing first patient Q4 2021 lymphoma De
Slide 9: Tumor cells co-opt the immune system to evade adaptive immunity
Tumor cells co-opt the immune system to evade adaptive immunity and promote oncogenesis in the TME The problem 9 Tumor Microenvironment (TME) 1 2 Tumors recruit Treg and Tumors use immature myeloid checkpoints to evade cells to create an immune response and immunosuppressive block activity of enviro
Slide 10: STAT3 is a master regulator of the immune system and a high-value I-O target
STAT3 is a master regulator of the immune system and a high- value immuno-oncology target, but requires cell-specific modulation STAT3 as an I-O target 10 STAT3 plays a major role in maintaining immunosuppression in the TME, however, it is important for cytotoxic T cell function Tumor cell Cytotoxic
Slide 11: Duet strategy: bi-functional oligonucleotide activates immune system and turns off STAT3
Duet strategy: bi-functional oligonucleotide activates immune system (TLR9) and turns off master checkpoint (STAT3) The Duet solution 11 1 2 Scavenger receptors, highly The bi-functional oligonucleotide is expressed in antigen-presenting internalized into early endosomes, cells, have a natural affin
Slide 12: DUET-01 results in complete response in A20 model of B-cell NHL
DUET-01 targets TLR9+ immune cells and results in complete response in A20 model of B-cell non-Hodgkin lymphoma siRNA for B-cell NHL 12 DUET-01 Time Dose CpG STAT3 siRNA Monocytes Targeted uptake of DUET-01 by TLR9+ immune cells pDCs and avoiding uptake by NK or T cells The DUET-01 oligonucleotide r
Slide 13: Phase I study of intratumoral DUET-01 with local radiation in relapsed/refractory B-cell NHL
A Phase I study of intratumoral injections of DUET-01 with local radiation in patients with relapsed/refractory B-cell NHL Phase 1 clinical trial 13 PRIMARY OBJECTIVES: • Determine the recommended Phase 2 dose of DUET-01 when given in combination with local radiation therapy. • Evaluate safety and f
Slide 14: Phase 1 trial evaluating three dose levels of DUET-01 with radiation
The Phase 1 clinical trial is evaluating three different dose levels of DUET-01 in combination with radiation therapy for B cell NHL Phase 1 clinical trial 14 DL3 ONLY DL3 ONLY CT PET 1 2 3 4 5 9 11 16 18 19 23 25 42 56 DLT assessment Primary tumor site Radiation (200 cGy) Secondary tumor sites CpG-
Slide 15: DUET-02 restores human T-cell proliferation and activity in prostate tumor microenvironment
DUET-02 restores human T-cell proliferation and activity in the prostate tumor microenvironment ASO for prostate cancer 15 DUET-02 CpG STAT3ASO Efficient and rapid (within 30 min of dosing) DUET- 02 uptake specifically by TLR9+ immune cells controlled by CpG-ODN1 The DUET-02 oligonucleotide results
Slide 16: DUET-02 induces T-cell mediated rejection of bone-localized and ICI-resistant prostate cancers
DUET-02 induces T-cell mediated rejection of bone-localized and ICI-resistant prostate cancers in mice ASO for prostate cancer 16 A Six intravenous injections of DUET-02 are Ras/Myc-driven tumors (RM9) Ras/Myc-driven (RM9) prostate cancer 1+1>2 sufficient to unleash potent antitumor effects and incr
Slide 17: DUET-02 generates CD8+ T-cell responses against HPV- head and neck cancer
DUET-02 generates effective CD8+ T-cell immune responses against human HPV- head and neck cancer (HNC) in humanized mice ASO for head & neck cancer 17 CpG-STAT3ASO (DUET-02) results in regression of xenotransplanted human head and neck tumors (SCC1) in humanized mice, with evidence of immune activat
Slide 18: Two planned Phase 1 trials to begin in Q1 2023
Duet is planning two clinical Phase 1 trials to begin in Q1 2023 for Genitourinary and Head & Neck Cancers Planned clinical trials 18 Genitourinary Cancers Head & Neck Cancers Systemic intravenous infusions of DUET-02 as a Intratumoral injection of DUET-02 in combination monotherapy for treatment of
Slide 19: Target milestones culminating in Phase 1 trials in three clinical indications
Target milestones that will culminate in Phase 1 clinical trials in three unique clinical indications Timeline & milestones 19 • Begin recruiting for genitourinary and head & neck cancers using DUET-02 • Begin combination study of • Launch of Duet Therapeutics DUET-01 + ICI through Scopus/Olimmune •
Slide 20: Duet leadership team
Duet is building a leadership team that has extensive company building and clinical development experience Leadership team 20 ALAN HORSAGER, PH.D. MARCIN KORTYLEWSKI, PH.D. President, CEO & Director Senior Scientific Advisor Other team members to be announced in the coming weeks
Slide 21: Contact
A Scopus BioPharma company Contact Alan Horsager, Ph.D. President – Immuno-Oncology, Scopus BioPharma President & CEO, Duet Therapeutics horsager@duettx.com
Scopus BioPharma — Investor Presentation (September 2021) on 6ix